Management Team

Vitae Pharmaceuticals’ executive management team and accomplished drug discovery scientists possess substantial experience across the full spectrum of drug discovery, development and commercialization.

The company’s Chief Executive Officer, Jeffrey S. Hatfield, previously held a number of executive and commercial positions at Bristol-Myers Squibb Company, or BMS, where he successfully launched products in several therapeutic areas. Richard Gregg, M.D., Vitae Pharmaceuticals’ Chief Scientific Officer, was previously head of Clinical Discovery of BMS, where he was involved in the development of all of BMS’ compounds from preclinical candidate selection through to human proof-of-concept. The company’s Chief Financial Officer, Richard Morris, previously worked at ViroPharma Incorporated and KPMG LLP in their Healthcare Assurance practice. Arthur Fratamico, R.Ph., Vitae Pharmaceuticals’ Chief Business Officer, previously served as chief business officer of Flexion Therapeutics, Inc., and led business development efforts at several private and public biotechnology companies including Trevena, Inc., Gemin X Pharmaceuticals, and MGI Pharma, Inc. Carole Sable, M.D., the company’s Chief Medical Officer, was previously Chief Medical Officer of REVOLUTION Medicines. Prior to Revolution Medicines, she served in similar roles in several pharmaceutical companies including SCYNEXIS Inc. as well as senior medical positions at Merck & Co.

In addition, Vitae Pharmaceuticals’ business and R&D teams are supported by a group of investors and advisors with significant expertise in developing pharmaceutical enterprises and enhancing their impact, capabilities and results.

Jeffrey S. HatfieldPresident & Chief Executive Officer

Richard Gregg, M.D.Chief Scientific Officer

Richard MorrisChief Financial Officer

Arthur Fratamico, R.Ph.Chief Business Officer

Carole Sable, M.D.Chief Medical Officer

David A. Claremon, Ph.D.Vice President, Chemistry

Gerard M. McGeehan, Ph.D.Vice President, Discovery Biology